Author

Elsa Quintana

Revolution Medicines (United States)ORCID 0000-0002-4123-1695Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:metagenomics· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Jacqueline A.M. SmithiD· 2 shared A. Cole EdwardsiD· 1 shared Álvaro Curiel‐GarcíaiD· 1 shared Amanda R. Decker-FarrelliD· 1 shared Amber M. AmparoiD· 1 shared Andrea CalifanoiD· 1 shared Andrea de CastroiD· 1 shared Andrew J. AguirreiD· 1 shared

Activity by Year

2024-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Jacqueline A.M. SmithORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyNature CommunicationsPeer-reviewedSep 25, 2024

Combining RASG12C(ON) inhibitor with SHP2 inhibition sensitises immune excluded lung tumours to immune checkpoint blockade: a strategy for turning cold tumours hot

Panayiotis Anastasiou, Christopher Moore, Sareena Rana…·Julian Downward

This paper shows that combining RASG12C(ON) and SHP2 inhibitors can make cold lung tumors responsive to immune checkpoint blockade by altering the tumor microenvironment and enhancing anti-tumor immunity.

39 citationstop 2%

mouseproteomics

𝕏 PostBluesky

Cancer BiologyNaturePeer-reviewedApr 8, 2024

Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma

Urszula N. Wasko, Jingjing Jiang, Tanner C. Dalton…·Kenneth P. Olive

This study evaluates the therapeutic potential of RMC-7977, a broad-spectrum RAS inhibitor, in pancreatic ductal adenocarcinoma models, showing strong anti-tumor effects with minimal impact on normal tissues.

225 citationstop 1%

humanmouse

𝕏 PostBluesky